Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hassan Website

Raffit Hassan, M.D.

Selected Publications

1)  Pastan I, Hassan R.
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy.
Cancer Res. 74: 2907-2912, 2014.
2)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
3)  Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D.
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Clin. Cancer Res. 16: 6132-8, 2010.
4)  Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers.
Clin. Cancer Res. 13: 5144-9, 2007.
5)  Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Clin. Cancer Res. 12: 447-53, 2006.
6)  Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM.
A Listeria Vaccine and Depletion of T-regulatory Cells Activate Immunity Against Early-stage Pancreatic Intra-epithelial Neoplasms and Prolong Survival of Mice.
Gastroenterology. [Epub ahead of print], 2014.
7)  Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA.
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Cancer. 120: 1145-54, 2014.
8)  Thomas A, Lee JH, Abdullaev Z, Park KS, Pineda M, Saidkhodjaeva L, Miettinen M, Wang Y, Pack SD, Giaccone G.
Characterization of fibroblast growth factor receptor 1 in small-cell lung cancer.
J Thorac Oncol. 9: 567-71, 2014.
9)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
10)  Jakopovic M, Thomas A, Lopez-Chavez A.
From platinum compounds to targeted therapies in advanced thoracic malignancies.
Anticancer Res. 34: 477-82, 2014.
11)  Thomas A, Jakopovic M.
Immunotherapy for non-small-cell lung cancer.
Expert Opin Biol Ther. 14: 1061-4, 2014.
12)  Miller AC, Miettinen M, Schrump DS, Hassan R.
Malignant Mesothelioma and Central Nervous System Metastases: Report of two cases, Pooled Analysis and Systematic Review.
Ann Am Thorac Soc. 2014.
13)  Chen Y, Gharwan H, Thomas A.
Novel biologic therapies for thymic epithelial tumors.
Front Oncol. 4: 103, 2014.
14)  Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Cancer. 2014.
15)  Tiseo M, Rajan A, Thomas A, Giaccone G.
"Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
J Thorac Oncol. 8: 511-2, 2013.
16)  Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman AW, Choyke P, Szabo E, Rajan A, Giaccone G.
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.
Clin. Cancer Res. 19: 1487-93, 2013.
17)  Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.
A novel nomogram for peritoneal mesothelioma predicts survival.
Ann. Surg. Oncol. 20: 555-61, 2013.
18)  Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I.
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Mol. Cancer Ther. 12: 48-57, 2013.
19)  Rajan A, Kotlyar D, Giaccone G.
Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma.
J Thorac Oncol. 8: e87-8, 2013.
20)  Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G.
Characterization and management of cardiac involvement of thymic epithelial tumors.
J Thorac Oncol. 8: 246-9, 2013.
21)  Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
Clin Lung Cancer. 14: 452-6, 2013.
22)  Thomas A, Maltzman J, Hassan R.
Farletuzumab in lung cancer.
Lung Cancer. 80: 15-8, 2013.
23)  Mossman BT, Shukla A, Heintz NH, Verschraegen CF, Thomas A, Hassan R.
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.
Am. J. Pathol. 182: 1065-77, 2013.
24)  Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE.
Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy.
Front Oncol. 3: 261, 2013.
25)  Petrini I, Rajan A, Pham T, Voeller D, Davis S, Gao J, Wang Y, Giaccone G.
Whole genome and transcriptome sequencing of a B3 thymoma.
PLoS ONE. 8: e60572, 2013.
26)  Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW, Eiden JE, Jaffee EM, Laheru DA.
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Clin. Cancer Res. 18: 858-68, 2012.
27)  Miller AC, Hassan R.
Clinical and pathological features are still the best determinants of prognosis in mesothelioma.
Oncology (Williston Park, N.Y.). 26: 1176, 1178, 1180, 2012.
28)  Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
PLoS ONE. 7: e31507, 2012.
29)  Kalra N, Zhang J, Yu Y, Ho M, Merino M, Cao L, Hassan R.
Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
Int J Cancer. 131: 2143-52, 2012.
30)  Thomas A, Hassan R.
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Lancet Oncol. 13: e301-10, 2012.
31)  Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R.
Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
Anticancer Res. 32: 5151-8, 2012.
32)  Kelly RJ, Sharon E, Pastan I, Hassan R.
Mesothelin-targeted agents in clinical trials and in preclinical development.
Mol. Cancer Ther. 11: 517-25, 2012.
33)  Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, Hassan R.
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Oncol. Rep. 27: 1794-800, 2012.
34)  Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I.
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012.
35)  Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R.
Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers.
Clin. Chem. Lab. Med. 50: 721-5, 2012.
36)  Kelly RJ, Sharon E, Hassan R.
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Lung Cancer. 73: 256-63, 2011.
37)  Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I.
Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Cancer Res. 71: 5915-22, 2011.
38)  Shin IS, Lee S, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH.
Effect of chelator conjugation level and injection dose on tumor and organ uptake of (111)In-labeled MORAb-009, an anti-mesothelin antibody.
Nucl Med Biol. 38: 1119-27, 2011.
39)  Feng M, Zhang J, Anver M, Hassan R, Ho M.
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.
J Cancer. 2: 123-31, 2011.
40)  Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH.
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Clin. Cancer Res. 17: 3697-705, 2011.
41)  Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M.
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
PLoS ONE. 6: e14640, 2011.
42)  Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I.
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Cancer Res. 70: 1082-9, 2010.
43)  Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I.
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Lung Cancer. 68: 455-9, 2010.
44)  Sarnovsky R, Tendler T, Makowski M, Kiley M, Antignani A, Traini R, Zhang J, Hassan R, FitzGerald DJ.
Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
Cancer Immunol. Immunother. 59: 737-46, 2010.
45)  Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH.
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
Proc. Natl. Acad. Sci. U.S.A. 106: 3360-5, 2009.
46)  Hassan R, Schweizer C, Lu K, Schuler B, Remaley A, Weil S, Pastan I.
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Lung Cancer. [Epub ahead of print], 2009.
47)  Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I.
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Clin. Cancer Res. 15: 5274-9, 2009.
48)  Walshe JM, Gal A, Murray DR, Premkumar A, Berman D, Hassan R.
Malignant mesothelioma of the inguinal canal with an unusually long survival.
Am. J. Clin. Oncol. 31: 306-7, 2008.
49)  Hassan R, Ho M.
Mesothelin targeted cancer immunotherapy.
Eur. J. Cancer. 44: 46-53, 2008.
50)  Hassan R, Pass H.
Physicians Information and Education Resource, American College of Physicians;; 2007. In Press. [Book]
51)  Yan T, Hassan R, Welch L, Sugarbaker P.
Advances in diffuse malignant peritoneal mesothelioma.
Oncol. Rev. 1: 53-64, 2007.
52)  Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J.
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Clin. Cancer Res. 13: 7166-71, 2007.
53)  Zhang Y, Xiang L, Hassan R, Pastan I.
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Proc. Natl. Acad. Sci. U.S.A. 104: 17099-104, 2007.
54)  Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ.
Immunotoxin treatment of cancer.
Annu. Rev. Med. 58: 221-37, 2007.
55)  Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I.
Mesothelin expression in human lung cancer.
Clin. Cancer Res. 13: 1571-5, 2007.
56)  Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, Hassan R, Gruhn B, Pastan I.
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Eur. J. Haematol. 79: 281-6, 2007.
57)  Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L.
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Cancer Immun. 7: 20, 2007.
58)  Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z, Wang M, Wang Q, Ho M, Beers R, Zhao H, Peng P, Zhou J, Li X, Petti G, Janjua A, Liu J, Wu D, Yu D, Zhang Z, Longley C, FitzGerald D, Kreitman RJ, Pastan I.
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Bioconjug. Chem. 18: 773-784, 2007.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/13/2014.